Pharmaceutical Company Achieves Milestone Promising Topline Results

Citius Pharmaceuticals, Inc. (Nasdaq: CTXR), a late-stage biopharmaceutical company specializing in the development and commercialization of first-in-class critical care products, has announced promising topline results from its pivotal Phase 3 clinical trial of Mino-Lok®, a novel antibiotic lock solution. Designed to salvage catheters in patients afflicted with central line-associated bloodstream infections (CLABSI) or catheter-related bloodstream infections (CRBSI), Mino-Lok demonstrated significant efficacy and safety in achieving primary and secondary endpoints. $Citius Pharmaceuticals (CTXR.US)$